Michael Locketz
Research Subjects
Research Interests
Michael Locketz has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Jake Ej Krige
University of Cape Town
4 shared publications - Adrian Calvin Bateman
Department of Cellular Pathology University Hospital Southampton NHS Foundation Trust Southampton UK
3 shared publications Anne Rullier
3 shared publications- Cheok Soon Lee
School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia
3 shared publications Corwyn Rowsell
3 shared publicationsDhirendra Govender
3 shared publications
Latest Publications
- Open Access
- 13 June 2023
- Published by AOSIS in South African Journal of Oncology
- Vol. 7
Gastrointestinal stromal tumours in patients presenting to an academic hospital in South Africa
The South African Journal of Oncology is a peer-reviewed on-line journal which publishes high quality articles on all aspects of oncology. The Editorial Board strongly supports a multidisciplinary approach to cancer care research as well as translational research in oncology.
- 13 June 2023
- Published by AOSIS in South African Journal of Oncology
- Vol. 7
Open AccessGastrointestinal stromal tumours in patients presenting to an academic hospital in South Africa
The South African Journal of Oncology is a peer-reviewed on-line journal which publishes high quality articles on all aspects of oncology. The Editorial Board strongly supports a multidisciplinary approach to cancer care research as well as translational research in oncology.
- Open Access
- 1 April 2021
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 59 (1) , 27a-27e
Neuroendocrine neoplasms of the digestive tract : incorporating the 2019 WHO grading schema in the South African context
Background: The classification of gastrointestinal (GI) neuroendocrine neoplasms (NENs) has been updated in the WHO classification of tumours of the digestive tract. Mitotic rate and Ki-67 proliferation index are central to the histopathological grading of these tumours. Assessing these variables is not standardised in local practice. This study addresses this deficit in the South African context. Methods: This is a retrospective audit of archival material of resection specimens of GI NENs (excluding appendix) at Groote Schuur Hospital from 2004 to 2017. We performed a mitotic count and immunohistochemistry for Ki-67 to reclassify tumours according to the 2019 WHO criteria. Results: Thirty-five resection specimens were examined. These represented stomach (n = 5), jejunoileum (n = 17), colon(n = 7) and rectum (n = 6). The mean age at the time of resection was 56 years (range 32-72). Twenty-one cases (60%)were women and 14 (40%) were men. The majority (24/35) of tumours were classified as grade 1 well-differentiatedneuroendocrine tumours (WD NETs), 8/35 were classified as grade 2 WD NETs and 3/35 were classified as small cell poorly differentiated neuroendocrine carcinomas (PD NECs). Re-classification resulted in 7/35 (20%) changes in tumour grade (4 upgraded, 3 downgraded). In most instances (7/8), the Ki-67 proliferation index was the determining factor in assigning tumour grade. Conclusion: This study has increased awareness of the recently updated WHO classification system. We conclude that an objective and systematic approach to counting of mitoses and determination of the Ki-67 proliferation index is recommended in routine practice.
- 1 April 2021
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 59 (1) , 27a-27e
Open AccessNeuroendocrine neoplasms of the digestive tract : incorporating the 2019 WHO grading schema in the South African context
Background: The classification of gastrointestinal (GI) neuroendocrine neoplasms (NENs) has been updated in the WHO classification of tumours of the digestive tract. Mitotic rate and Ki-67 proliferation index are central to the histopathological grading of these tumours. Assessing these variables is not standardised in local practice. This study addresses this deficit in the South African context. Methods: This is a retrospective audit of archival material of resection specimens of GI NENs (excluding appendix) at Groote Schuur Hospital from 2004 to 2017. We performed a mitotic count and immunohistochemistry for Ki-67 to reclassify tumours according to the 2019 WHO criteria. Results: Thirty-five resection specimens were examined. These represented stomach (n = 5), jejunoileum (n = 17), colon(n = 7) and rectum (n = 6). The mean age at the time of resection was 56 years (range 32-72). Twenty-one cases (60%)were women and 14 (40%) were men. The majority (24/35) of tumours were classified as grade 1 well-differentiatedneuroendocrine tumours (WD NETs), 8/35 were classified as grade 2 WD NETs and 3/35 were classified as small cell poorly differentiated neuroendocrine carcinomas (PD NECs). Re-classification resulted in 7/35 (20%) changes in tumour grade (4 upgraded, 3 downgraded). In most instances (7/8), the Ki-67 proliferation index was the determining factor in assigning tumour grade. Conclusion: This study has increased awareness of the recently updated WHO classification system. We conclude that an objective and systematic approach to counting of mitoses and determination of the Ki-67 proliferation index is recommended in routine practice.
- 13 February 2020
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 28 (5) , 514-516
Blastic Plasmacytoid Dendritic Cell Neoplasm: An Uncommon Entity to Consider in the Differential Diagnosis of Cutaneous Lymphoma
Cutaneous lymphomas are encountered infrequently in general surgical pathology practice, and the broad array of pathological entities poses a diagnostic challenge. Integration of clinical information, results of additional laboratory investigations, and an extensive immunohistochemical panel are essential in arriving at the correct diagnosis. We present a case of blastic plasmacytoid dendritic cell neoplasm that occurred in an unusual clinical setting. This case highlights the need for a broad differential diagnosis and an extensive immunohistochemical workup when approaching a cutaneous lymphoma.
- 13 February 2020
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 28 (5) , 514-516
Blastic Plasmacytoid Dendritic Cell Neoplasm: An Uncommon Entity to Consider in the Differential Diagnosis of Cutaneous Lymphoma
Cutaneous lymphomas are encountered infrequently in general surgical pathology practice, and the broad array of pathological entities poses a diagnostic challenge. Integration of clinical information, results of additional laboratory investigations, and an extensive immunohistochemical panel are essential in arriving at the correct diagnosis. We present a case of blastic plasmacytoid dendritic cell neoplasm that occurred in an unusual clinical setting. This case highlights the need for a broad differential diagnosis and an extensive immunohistochemical workup when approaching a cutaneous lymphoma.
- 20 April 2019
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 220 (5) , 841-851
The Contribution of Kaposi’s Sarcoma–Associated Herpesvirus to Mortality in Hospitalized Human Immunodeficiency Virus–Infected Patients Being Investigated for Tuberculosis in South Africa
Despite increasing numbers of human immunodeficiency virus (HIV)–infected South Africans receiving antiretroviral therapy (ART), tuberculosis (TB) remains the leading cause of mortality. Approximately 25% of patients treated for TB have microbiologically unconfirmed diagnoses. We assessed whether elevated Kaposi’s sarcoma–associated herpesvirus (KSHV) viral load (VL) contributes to mortality in hospitalized HIV-infected patients investigated for TB. Six hundred eighty-two HIV-infected patients admitted to Khayelitsha Hospital, South Africa, were recruited, investigated for TB, and followed for 12 weeks. KSHV serostatus, peripheral blood KSHV-VL, and KSHV-associated clinical correlates were evaluated. Median CD4 count was 62 (range, 0–526) cells/μL; KSHV seropositivity was 30.7% (95% confidence interval [CI], 27%–34%); 5.8% had detectable KSHV-VL (median, 199.1 [range, 13.4–2.2 × 106] copies/106 cells); 22% died. Elevated KSHV-VL was associated with mortality (adjusted odds ratio, 6.5 [95% CI, 1.3–32.4]) in patients without TB or other microbiologically confirmed coinfections (n = 159). Six patients had “possible KSHV-inflammatory cytokine syndrome” (KICS): 5 died, representing significantly worse survival (P < .0001), and 1 patient was diagnosed with KSHV-associated multicentric Castleman disease at autopsy. Given the association of mortality with elevated KSHV-VL in critically ill HIV-infected patients with suspected but not microbiologically confirmed TB, KSHV-VL and KICS criteria may guide diagnostic and therapeutic evaluation.
- 20 April 2019
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 220 (5) , 841-851
The Contribution of Kaposi’s Sarcoma–Associated Herpesvirus to Mortality in Hospitalized Human Immunodeficiency Virus–Infected Patients Being Investigated for Tuberculosis in South Africa
Despite increasing numbers of human immunodeficiency virus (HIV)–infected South Africans receiving antiretroviral therapy (ART), tuberculosis (TB) remains the leading cause of mortality. Approximately 25% of patients treated for TB have microbiologically unconfirmed diagnoses. We assessed whether elevated Kaposi’s sarcoma–associated herpesvirus (KSHV) viral load (VL) contributes to mortality in hospitalized HIV-infected patients investigated for TB. Six hundred eighty-two HIV-infected patients admitted to Khayelitsha Hospital, South Africa, were recruited, investigated for TB, and followed for 12 weeks. KSHV serostatus, peripheral blood KSHV-VL, and KSHV-associated clinical correlates were evaluated. Median CD4 count was 62 (range, 0–526) cells/μL; KSHV seropositivity was 30.7% (95% confidence interval [CI], 27%–34%); 5.8% had detectable KSHV-VL (median, 199.1 [range, 13.4–2.2 × 106] copies/106 cells); 22% died. Elevated KSHV-VL was associated with mortality (adjusted odds ratio, 6.5 [95% CI, 1.3–32.4]) in patients without TB or other microbiologically confirmed coinfections (n = 159). Six patients had “possible KSHV-inflammatory cytokine syndrome” (KICS): 5 died, representing significantly worse survival (P < .0001), and 1 patient was diagnosed with KSHV-associated multicentric Castleman disease at autopsy. Given the association of mortality with elevated KSHV-VL in critically ill HIV-infected patients with suspected but not microbiologically confirmed TB, KSHV-VL and KICS criteria may guide diagnostic and therapeutic evaluation.
- Open Access
- 1 January 2019
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 57 (2) , 66-67
Papillary renal cell carcinoma presenting as a renal abscess
- 1 January 2019
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 57 (2) , 66-67
Open AccessPapillary renal cell carcinoma presenting as a renal abscess
- 8 October 2018
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (10-11) , 1217-1221
CD73 expression in tissue granulomas in distinguishing intestinal tuberculosis from Crohn’s disease in a South African cohort
Introduction: Overlap of clinical, endoscopic and radiographic features, coupled with a poor microbiological yield makes differentiating Crohn’s disease (CD) from intestinal tuberculosis (ITB) challenging. A potential histological differentiating mechanism is the use of immunohistochemical staining for the mesenchymal stem cell marker CD73, as a pilot study showed ITB but not CD granulomas stained positive for this marker. The aim of this study was to assess the value of CD73 in differentiating ITB from CD granulomas in a South African cohort. Methods: Patients with confirmed CD or ITB were identified from a pathology database. Tissue sections were reviewed by a pathologist to confirm the presence of granulomas. These were then stained with a mouse monoclonal anti-CD73 antibody. The slides were examined together by a pathologist and gastroenterologist in a blinded manner for anti-CD73 staining around granulomas. Results: Ninety six cases were available for analysis; 50 cases of ITB and 46 cases of CD. Thirty percent of CD granulomas (14/46) stained positive for CD73, whereas CD73 positivity was seen in 52% (26/50) of cases of ITB. This was statistically significant (OR 2.48, 95% CI 1.1–5.72, p = .03). The area under the curve (AUC) was 0.61. Sensitivity of CD73 in predicting ITB was 52% and specificity was 70%. Overall CD73 staining of granulomas correctly classified only 60% of cases. Conclusions: In our study we have shown that significantly more patients with ITB express CD73 in their granulomas than those with CD. However the relatively poor sensitivity, specificity and AUC make this test unlikely to be of value in our clinical practice.
- 8 October 2018
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (10-11) , 1217-1221
CD73 expression in tissue granulomas in distinguishing intestinal tuberculosis from Crohn’s disease in a South African cohort
Introduction: Overlap of clinical, endoscopic and radiographic features, coupled with a poor microbiological yield makes differentiating Crohn’s disease (CD) from intestinal tuberculosis (ITB) challenging. A potential histological differentiating mechanism is the use of immunohistochemical staining for the mesenchymal stem cell marker CD73, as a pilot study showed ITB but not CD granulomas stained positive for this marker. The aim of this study was to assess the value of CD73 in differentiating ITB from CD granulomas in a South African cohort. Methods: Patients with confirmed CD or ITB were identified from a pathology database. Tissue sections were reviewed by a pathologist to confirm the presence of granulomas. These were then stained with a mouse monoclonal anti-CD73 antibody. The slides were examined together by a pathologist and gastroenterologist in a blinded manner for anti-CD73 staining around granulomas. Results: Ninety six cases were available for analysis; 50 cases of ITB and 46 cases of CD. Thirty percent of CD granulomas (14/46) stained positive for CD73, whereas CD73 positivity was seen in 52% (26/50) of cases of ITB. This was statistically significant (OR 2.48, 95% CI 1.1–5.72, p = .03). The area under the curve (AUC) was 0.61. Sensitivity of CD73 in predicting ITB was 52% and specificity was 70%. Overall CD73 staining of granulomas correctly classified only 60% of cases. Conclusions: In our study we have shown that significantly more patients with ITB express CD73 in their granulomas than those with CD. However the relatively poor sensitivity, specificity and AUC make this test unlikely to be of value in our clinical practice.
- Open Access
- 1 September 2018
- Published by Springer Nature in African Journal of Urology
- Vol. 24 (3) , 175-179
Giant angiomyolipoma in a tuberous sclerosis patient and review of the literature
- 1 September 2018
- Published by Springer Nature in African Journal of Urology
- Vol. 24 (3) , 175-179
Open AccessGiant angiomyolipoma in a tuberous sclerosis patient and review of the literature
- Open Access
- 8 March 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (3) , e0006173
Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy
A 42-year-old male from an urban informal settlement in Cape Town, South Africa, was seen at a tertiary-care hospital for progressively enlarging lesions on his nose. He had initially presented to medical care 6 months earlier with a 3-month history of anorexia, weight loss, nonproductive cough, and nasal congestion. An HIV test was reactive, and his CD4 count was 32 cells/μL. He also had renal insufficiency with a creatinine clearance of 40 mL/min. Two weeks after diagnosis, he was initiated on antiretroviral therapy (ART) consisting of lamivudine (150 mg by mouth twice daily), stavudine (30 mg by mouth twice daily), and efavirenz (600 mg by mouth once daily). One week later, he developed widespread erythematous nodules and plaques on his face and a crusted mass on his nose (Fig 1A). A chest X-ray demonstrated a reticular opacity within the right middle lobe. A skin biopsy of a facial plaque demonstrated a minimal inflammatory response (Fig 1B). Methenamine silver staining revealed small (3-5μm) yeast-like cells with occasional narrow-based budding (Fig 1C). Fungal culture of skin tissue and blood grew Emergomyces africanus (formerly Emmonsia sp.); identification was confirmed by sequencing of the internal transcribed spacer region (ITS). He was treated with intravenous amphotericin B deoxycholate (1 mg/kg) for 14 days. Thereafter, his ART was changed to lamivudine (150 mg by mouth twice daily), zidovudine (300 mg by mouth twice daily), and combination lopinovir/ritonavir (400/100 mg by mouth twice daily), and he was commenced on itraconazole (200 mg capsule orally once daily, to be taken with food) to continue for 1 year pending immune reconstitution. Soon after initiating antifungal therapy, the patient's constitutional and respiratory symptoms abated, and the cutaneous lesions improved over several weeks. However, the nasal lesions never completely resolved despite reported adherence to ART and itraconazole. Approximately 4 months after completing amphotericin B, his nasal lesions worsened over 1 month and he was referred to our tertiary-care centre for further evaluation.
- 8 March 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (3) , e0006173
Open AccessParadoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy
A 42-year-old male from an urban informal settlement in Cape Town, South Africa, was seen at a tertiary-care hospital for progressively enlarging lesions on his nose. He had initially presented to medical care 6 months earlier with a 3-month history of anorexia, weight loss, nonproductive cough, and nasal congestion. An HIV test was reactive, and his CD4 count was 32 cells/μL. He also had renal insufficiency with a creatinine clearance of 40 mL/min. Two weeks after diagnosis, he was initiated on antiretroviral therapy (ART) consisting of lamivudine (150 mg by mouth twice daily), stavudine (30 mg by mouth twice daily), and efavirenz (600 mg by mouth once daily). One week later, he developed widespread erythematous nodules and plaques on his face and a crusted mass on his nose (Fig 1A). A chest X-ray demonstrated a reticular opacity within the right middle lobe. A skin biopsy of a facial plaque demonstrated a minimal inflammatory response (Fig 1B). Methenamine silver staining revealed small (3-5μm) yeast-like cells with occasional narrow-based budding (Fig 1C). Fungal culture of skin tissue and blood grew Emergomyces africanus (formerly Emmonsia sp.); identification was confirmed by sequencing of the internal transcribed spacer region (ITS). He was treated with intravenous amphotericin B deoxycholate (1 mg/kg) for 14 days. Thereafter, his ART was changed to lamivudine (150 mg by mouth twice daily), zidovudine (300 mg by mouth twice daily), and combination lopinovir/ritonavir (400/100 mg by mouth twice daily), and he was commenced on itraconazole (200 mg capsule orally once daily, to be taken with food) to continue for 1 year pending immune reconstitution. Soon after initiating antifungal therapy, the patient's constitutional and respiratory symptoms abated, and the cutaneous lesions improved over several weeks. However, the nasal lesions never completely resolved despite reported adherence to ART and itraconazole. Approximately 4 months after completing amphotericin B, his nasal lesions worsened over 1 month and he was referred to our tertiary-care centre for further evaluation.
- Open Access
- 24 December 2016
- Published by Springer Nature in African Journal of Urology
- Vol. 23 (1) , 62-65
An atypical cause of retroperitoneal fibrosis: Case report and literature review
- 24 December 2016
- Published by Springer Nature in African Journal of Urology
- Vol. 23 (1) , 62-65
Open AccessAn atypical cause of retroperitoneal fibrosis: Case report and literature review
- 26 September 2016
- Published by BMJ in Journal of Clinical Pathology
- Vol. 70 (4) , 331-356
The role of miRNA-21 and epithelial mesenchymal transition (EMT) process in colorectal cancer
Aims: The study was conducted to assess the expression levels of epithelial mesenchymal transition (EMT) proteins (E-cadherin, N-cadherin, snail-1 and vimentin) and miRNA-21. In addition, we correlated these data with clinicopathological features in Colorectal cancer. Methods: H&E slides from a total of 59 formalin fixed paraffin embedded tissue blocks were examined by a pathologist to demarcate normal and tumour regions. Immunohistochemical analysis of mismatch repair proteins (MLH1, MSH2 and MSH6) and EMT markers (E-cadherin, N-cadherin, snail-1 and vimentin) was performed. The miRNA-21 expression levels were determined using qRT-PCR and the data was analysed using the relative quantification method. The Fisher's exact and Pearson's χ 2 tests were used to correlate snail-1, E-cadherin, miRNA-21 and clinicopathological data. Results: Our results showed a statistically significant correlation between high miRNA-21 expression levels and E-cadherin positive cases. There was also an association between high miRNA-21 expression levels and negative snail-1 expression. No significant correlation was seen between miRNA-21 expression levels and clinicopathological features. Moreover, high expression levels of miRNA-21 were significantly associated with the sporadic cases. Conclusions: Our data suggest that miRNA-21 in association with E-cadherin and snail-1 does not play a significant role in the development and progression of this disease.
- 26 September 2016
- Published by BMJ in Journal of Clinical Pathology
- Vol. 70 (4) , 331-356
The role of miRNA-21 and epithelial mesenchymal transition (EMT) process in colorectal cancer
Aims: The study was conducted to assess the expression levels of epithelial mesenchymal transition (EMT) proteins (E-cadherin, N-cadherin, snail-1 and vimentin) and miRNA-21. In addition, we correlated these data with clinicopathological features in Colorectal cancer. Methods: H&E slides from a total of 59 formalin fixed paraffin embedded tissue blocks were examined by a pathologist to demarcate normal and tumour regions. Immunohistochemical analysis of mismatch repair proteins (MLH1, MSH2 and MSH6) and EMT markers (E-cadherin, N-cadherin, snail-1 and vimentin) was performed. The miRNA-21 expression levels were determined using qRT-PCR and the data was analysed using the relative quantification method. The Fisher's exact and Pearson's χ 2 tests were used to correlate snail-1, E-cadherin, miRNA-21 and clinicopathological data. Results: Our results showed a statistically significant correlation between high miRNA-21 expression levels and E-cadherin positive cases. There was also an association between high miRNA-21 expression levels and negative snail-1 expression. No significant correlation was seen between miRNA-21 expression levels and clinicopathological features. Moreover, high expression levels of miRNA-21 were significantly associated with the sporadic cases. Conclusions: Our data suggest that miRNA-21 in association with E-cadherin and snail-1 does not play a significant role in the development and progression of this disease.